Search Results
Search results for "neuroma model"
Results found for "neuroma model"
- Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem
Her work spans GPCR structural biology, membrane protein stabilization, allosteric modulation, and the extra-helical pockets on the glucagon receptor, intracellular sites for C5a antagonists, allosteric modulators only survives translation if the coupling profile in the relevant human cells matches the cell-line model Marshall's caution is hard-won: many animal-model-validated GPCR drugs have failed in the clinic precisely wave of GPCR drug design 18:47 Which GPCR families pharma is chasing now — and why 21:23 Why animal model
- GPCR Retreat | Dr. GPCR Ecosystem
University in Australia, one of the pioneers in the medicinal chemistry, computational and mathematical modelling scientists working in the arenas of structure and signaling, neuroscience, cancer, translational and model
- Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem
steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models Slosky characterized a new class of β-arrestin biased allosteric modulators (BAMs) for the neurotensin Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects
- FAQ | Dr. GPCR Ecosystem
Each session explores mechanistic models, translational challenges, and real-world therapeutic implications
- Dr. GPCR Board | Dr. GPCR Ecosystem
critical expertise, and rigorous approaches to examine PAR1 function using human cultured cells and mouse models San Diego Supercomputer Center, and provided consultation for genetic sequence analysis, molecular modeling
- Your GPCR Order Has Arrived! ❇ Feb 10 - 16, 2025 | Dr. GPCR Ecosystem
During these four sessions, you'll dive into: Advanced pharmacokinetic modeling The Druglike Quality ✅ Practical Quantification of Allosteric Modulation – May 1, 2025 ✅ Applying the Black/Leff Operational Model to Predict Agonism – October 2, 2025 Premium Members save 25% on enrollment. 2nd GPCR signaling and drug discovery Symposium & Workshop NEW April 2 - 3, 2025 | New therapeutic modalities
- Dr. Lukas Grätz | Dr. GPCR Ecosystem
My initial focus was on creating an automated chimeric homology modeling pipeline for GPCRs and since
- Gáspár Pándy-Szekeres | Dr. GPCR Ecosystem
My initial focus was on creating an automated chimeric homology modeling pipeline for GPCRs and since
- Dr. Kenneth A. Jacobson | Dr. GPCR Ecosystem
He adapts interdisciplinary approaches (synthesis, modeling, pharmacology) to study G protein-coupled
- Dr. Graham Ladds | Dr. GPCR Ecosystem
His research group uses a combination of pharmacological investigations and mathematical modeling to
- Dr. Benjamin Myers | Dr. GPCR Ecosystem
transmembrane receptors, combining biochemical and structural approaches with cell biology and in vivo models
- Dr. Marta Filizola | Dr. GPCR Ecosystem
computational structural biology tools and rational drug design approaches, ranging from molecular modeling
- Developing new tools to uncover GPCR signaling patterns with Remi Janicot | Dr. GPCR Ecosystem
Overall, the lab works on diverse models and diseases, and has developed a wide array of tools to dissect
- Dr. Nicola J. Smith | Dr. GPCR Ecosystem
the understanding of how an orphan GPCR exerts its effects both in vitro (cell culture and ex vivo models
- Dr. Sai Prasad Pydi | Dr. GPCR Ecosystem
His laboratory uses knock-out and transgenic mouse models, along with different cell culture systems,
- Dr. Tobi Langenhan | Dr. GPCR Ecosystem
I work with invertebrate animal models (mainly D. melanogaster) and in vitro techniques to pick apart adhesion GPCRs, and extends to the development of novel screening approaches to identify pharmacological modulators
- Dr. Kathleen Caron | Dr. GPCR Ecosystem
steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models
- Dr. Nariman Balenga | Dr. GPCR Ecosystem
the role of RGS4 and RGS5 in airway hyperresponsiveness and lung fibrosis in acute and chronic mouse models A fungal serine protease allergen with GPCR-modulating features was discovered as a new biomarker and
- Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural and chemical biology , molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease
- Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural and chemical biology , molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease
- Anything BUT GPCRs with Dr. Mikel Garcia-Marcos | Dr. GPCR Ecosystem
(biochemistry, cell biology, genetics) and experimental systems (purified proteins, cultured cells, model
- Sam Hoare: Receptor Residence Time and GPCR Data Analysis | Dr. GPCR Ecosystem
Sam Hoare brings a data analyst's perspective to GPCR pharmacology — one trained in allosteric modulation After a PhD on allosteric modulation of dopamine receptors in Philip Strange's UK lab and a postdoc at biotech and pharmaceutical clients on GPCR data analysis, receptor binding kinetics, and pharmacological modeling The underlying pharmacological theory, from operational models of agonism to allosteric binding equations Samuel Hoare Sam completed his Ph.D. in biochemistry, studying allosteric modulation of dopamine receptors
- Paul Insel: Unbiased Discovery and the GPCRs We've Been Missing | Dr. GPCR Ecosystem
combines bioinformatic analysis of GPCR expression across human cancers with wet-lab validation in animal models studied receptor function in human physiology, receptor molecular pharmacology in cells, and animal models
- Dr. JoAnn Trejo | Dr. GPCR Ecosystem
critical expertise, and rigorous approaches to examine PAR1 function using human cultured cells and mouse models
- Dr. Simone Prömel & Dr. Ines Liebscher | Dr. GPCR Ecosystem
There she focused on the different modes of action of Adhesion GPCRs and found that they do not only different signals on a molecular level and how these are translated into physiological functions in various model
- Dr. Jean Martin Beaulieu | Dr. GPCR Ecosystem
The Beaulieu group is presently investigating how cell surface express proteins can act as allosteric modulators Translational validation is important to validate findings obtained from experimental models research
- Dr. Lauren M. Slosky | Dr. GPCR Ecosystem
Slosky characterized a new class of β-arrestin biased allosteric modulators (BAMs) for the neurotensin Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects
- David Gloriam: Orphan Receptors, GPCRDB, and the Data Revolution in GPCR Pharmacology | Dr. GPCR Ecosystem
The result was a structured group management model built around four specialized subgroups, each with 15 - subgroups, leadership training, and delegation 40:41 What excites Gloriam today - open science models
- Kari Johnson: mGlu2, Addiction, and the Brain Circuits Alcohol Rewires | Dr. GPCR Ecosystem
By suppressing glutamate release across circuits in the basal ganglia, mGlu2 is positioned to modulate this receptor from the bench to the behaving animal, using optogenetics and circuit-selective mouse models her early tools could not fully answer, she made the shift to optogenetics and genetically defined neuronal neuromodulation by GPCRs - using light-activated ion channels expressed in anatomically or genetically defined neurons modulomics - studying circuit-specific GPCR function in the basal ganglia 20:45 Operant behavioral models
- Kathryn Livingston: Allosteric Opioid Modulators and Receptor Signaling Beyond the Membrane | Dr. GPCR Ecosystem
Livingston on allosteric opioid modulators, receptor internalization, and navigating the transition from research to biotech. << Back to podcast list Strategic Partner(s) Kathryn Livingston: Allosteric Opioid Modulators The first allosteric modulators of opioid receptors were discovered through an academic-industry collaboration Equilibrium vs. dynamic frameworks for studying receptor biology The Field Application Scientist as a career model Allosteric opioid modulators bypass the orthosteric site entirely Rather than competing with morphine





























